KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Capital Expenditures (2017 - 2025)

Twist Bioscience (TWST) has disclosed Capital Expenditures for 9 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 366.95% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.8 million through Dec 2025, up 528.15% year-over-year, with the annual reading at $28.0 million for FY2025, 451.69% up from the prior year.
  • Capital Expenditures for Q4 2025 was $10.0 million at Twist Bioscience, down from $26.2 million in the prior quarter.
  • The five-year high for Capital Expenditures was $40.6 million in Q2 2022, with the low at -$1.5 million in Q1 2024.
  • Average Capital Expenditures over 5 years is $9.8 million, with a median of $7.5 million recorded in 2021.
  • The sharpest move saw Capital Expenditures plummeted 116.09% in 2024, then skyrocketed 1207.79% in 2025.
  • Over 5 years, Capital Expenditures stood at $12.8 million in 2021, then fell by 7.5% to $11.8 million in 2022, then tumbled by 87.26% to $1.5 million in 2023, then surged by 41.83% to $2.1 million in 2024, then soared by 366.95% to $10.0 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $10.0 million, $26.2 million, and $493000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.